Universe Pharmaceuticals (UPC) Financial Statements & Analysis

Universe Pharmaceuticals (UPC) Income Statement

Universe Pharmaceuticals reported revenue of $17.86M in fiscal 2025 (fiscal year ended Sep 30, 2025), down 22.4% from $23.02M a year earlier. Universe Pharmaceuticals posted a net loss of $3.67M, compared with a net loss of $8.73M a year earlier. Gross margin was 35.3% and operating margin -16.3%. In the most recent quarter, Q2 fiscal 2026 (ended Mar 31, 2026), revenue was $9.04M, down 1.3% from the same quarter a year earlier.

Universe Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Universe Pharmaceuticals INC income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018
Revenue & Gross Profit
Revenue	17.86	23.02	32.31	40.14	47.98	30.70	33.23	28.51
Cost of Revenue	11.56	16.95	21.99	18.25	22.66	16.61	19.82	15.11
Gross Profit	6.30	6.07	10.32	21.89	25.33	14.09	13.41	13.41
Operating Expenses
Research & Development	0.67	3.60	4.86	7.64	5.47	0.58	0.62	0.79
Selling, General & Administrative	8.00	9.88	9.33	21.27	6.27	2.80	2.29	2.39
Operating Expenses	9.22	14.09	14.28	28.91	11.74	3.74	3.36	3.65
Operating Income	-2.92	-8.02	-3.97	-7.02	13.59	10.25	9.75	9.66
Other Income/Expense
Interest Income	0.00	0.00	31.07	0.04	0.00	0.00	0.00	0.00
Interest Expense	0.23	0.28	-0.19	-0.20	0.10	0.12	0.13	0.16
Other Income/Expense	-0.76	0.18	-0.36	-0.07	0.06	-0.15	-0.10	-0.14
Income
Income Before Tax	-3.67	-8.12	-4.33	-7.09	13.65	10.10	9.65	9.52
Income Tax Expense	0.00	0.61	-2.25	-0.82	2.36	2.54	2.10	1.92
Net Income	-3.67	-8.73	-6.58	-7.91	11.32	7.56	7.55	7.60
Net Income - Continuous Operations	-3.67	-8.73	-6.58	-7.91	11.32	7.56	7.55	7.60
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-
EBITDA	-2.92	-7.36	-3.46	-6.49	14.20	10.61	10.17	10.11
EBIT	-2.92	-7.84	-3.97	-7.02	13.59	-	-	-
Depreciation & Amortization	0.52	0.21	0.51	0.53	0.45	0.41	0.42	0.45
Earnings Per Share
Basic EPS	-1056.00	-627.00	-1089.00	-1309.00	2147.00	1296.00	1295.00	1303.00
Diluted EPS	-1056.00	-627.00	-1089.00	-1309.00	2147.00	1296.00	1295.00	1303.00
Basic Shares Outstanding	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Diluted Shares Outstanding	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.01

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Universe Pharmaceuticals Financial Statements

What was Universe Pharmaceuticals's revenue in fiscal 2025?

Universe Pharmaceuticals reported revenue of $17.86M in fiscal 2025 (fiscal year ended Sep 30, 2025). That was down 22.4% from $23.02M a year earlier.

Is Universe Pharmaceuticals profitable?

No. Universe Pharmaceuticals reported a net loss of $3.67M in fiscal 2025. In fiscal 2024 it lost $8.73M.

What is Universe Pharmaceuticals's operating margin?

Universe Pharmaceuticals's operating income was −$2.92M on revenue of $17.86M in fiscal 2025, an operating margin of -16.3%, compared with -34.8% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition